<!DOCTYPE html>
<html lang="en">
	<head>
		<meta charset="utf8">
		<meta name="viewport" content="width=device-width, initial-scale=1">
		<title>Risteys – M13_ANKYLOSPON_STRICT – detailed case counts by code</title>
		<style type="text/css">
body {
	font-family: sans-serif;
}
.bar-plot-full {
	width: 8rem;
	border-radius: 0.1rem;
	background-color: #f2f2f2;
}
.bar-plot-full div {
	background-color: #c7c7c7;
	height: 1rem;
	border-radius: 0.1rem;
}
		</style>
	</head>
	<body>

		<table>
			<tr>
				<th>Source</th>
				<th>Code</th>
				<th>Name</th>
				<th>Case count</th>
				<th>Share of cases (%)</th>
			</tr>

			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(202)_ICD10(M45)</td>
					<td>Connective tissue diseases, rheumatoid arthritis and comparable disease, Ankylosing spondylitis</td>
					<td>857</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 79.8695246971109%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(313)_ICD10(M45)</td>
					<td>Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab, tocilizumab and ustekinumab (rheumatoid diseases), Ankylosing spondylitis</td>
					<td>621</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 57.875116495806154%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(281)_ICD10(M45)</td>
					<td>Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab and tocilizumab, Ankylosing spondylitis</td>
					<td>596</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 55.54520037278658%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(313)_ICD10(M450)</td>
					<td>Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab, tocilizumab and ustekinumab (rheumatoid diseases), Name not found</td>
					<td>16</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 1.4911463187325256%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(281)_ICD10(M450)</td>
					<td>Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab and tocilizumab, Name not found</td>
					<td>14</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 1.30475302889096%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(202)_ICD10(M450)</td>
					<td>Connective tissue diseases, rheumatoid arthritis and comparable disease, Name not found</td>
					<td>7</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 0.65237651444548%"></div>
						</div>
						
					</td>
				</tr>
			

		</table>

	</body>
</html>
